Study of chromosomal abnormalities by fluorescent in-situ-hyberdisation (FISH), and quantitative polymerase chain reaction (qPCR) in Multiple Myeloma patients and correlations with treatment outcomes.

Not Applicable

Recruiting

• Conditions: Chromosomal Abnormalities in Multiple Myeloma; Cancer - Myeloma; Blood - Haematological diseases

• Registration Number: ACTRN12609000594224
• Lead Sponsor: Clifford Craig Medical Research Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-07-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients who are newly diagnosed with multiple myeloma or who has relpased multiple myeloma and are above 18 years old.

Exclusion Criteria

Patients under 18 years. Since this is an observational study, no other exclusion criteria.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This study aims at evaluating the prognostic value of chromosome 13 deletions as well as t(4,14) as detected <br>by the FISH/qPCR techniques in multiple myeloma patients. The impact of these abnormalities in the context of high-dose therapy (HDT) or conventional therapy will help to identify those patients who would maximallybenefit from HDT and those who would be refractory to HDT and might benefit from other therapeutic options.[at diagnosis of multiple myeloma or at time of relapse of the disease]

Secondary Outcome Measures

Name	Time	Method
Study of the prevalence of these chromosomal abnormalities in newly diagnosed and relapsed multiple myeloma.[yearly for 4 years ending in Dec 2011.]